TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Ondine Biomedical, Inc. ( (GB:OBI) ).
Ondine Biomedical Inc. has announced that its Steriwave photodisinfection technology is 99.9% effective against the drug-resistant fungus C. auris, which has seen a 67% increase in cases in EU hospitals over the last year. This development is significant as C. auris poses a major threat to healthcare systems due to its resistance to most disinfectants and high mortality rate, with the potential to incur substantial costs in containment and treatment. Ondine’s technology offers a promising solution to manage the rising burden of invasive fungal infections, which have become a growing public health concern worldwide.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical is a global leader in photodisinfection technology, dedicated to delivering innovative solutions to combat antimicrobial resistance and healthcare-associated infections. With proven success in reducing pathogen transmission and outbreaks, Ondine remains at the forefront of preventing infectious disease threats in hospitals worldwide.
Average Trading Volume: 391,899
Technical Sentiment Signal: Buy
Current Market Cap: £79.05M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.